Formulary
Elbasvir with grazoprevir: Indications, Dosing, Side Effects and Interactions
For elbasvir with grazoprevir Elbasvir is an HCV NS5A inhibitor and grazoprevir is an HCV NS3/4A protease inhibitor; they reduce viral load by inhibiting...
MedNext Academy | 3 min read
Elbasvir with grazoprevir: Indications, Dosing, Side Effects and Interactions
For elbasvir with grazoprevir Elbasvir is an HCV NS5A inhibitor and grazoprevir is an HCV NS3/4A protease inhibitor; they reduce viral load by inhibiting...
Drug action
For elbasvir with grazoprevir Elbasvir is an HCV NS5A inhibitor and grazoprevir is an HCV NS3/4A protease inhibitor; they reduce viral load by inhibiting hepatitis C virus RNA replication.
Indications and dose
**Chronic hepatitis C infection of genotypes 1 or 4 [with or without ribavirin] (initiated by a specialist)**
- **Adult** (By Mouth): 50/100 mg once daily for 12 weeks (may extend to 16 weeks in some circumstances-consult product literature).
**Chronic hepatitis C infection of genotypes 1 or 4 [with or without ribavirin] (initiated by a specialist) for elbasvir with grazoprevir**
- **Child 12-17 years (body-weight 30 kg and above)** (By mouth): 50/100 mg once daily for 12 weeks (may extend to 16 weeks in some circumstances-consult product literature).
Cautions
For elbasvir with grazoprevir Hepatitis B co-infection; re-treatment following previous exposure to elbasvir with grazoprevir, or to drugs of the same classes (NS5A inhibitors or NS3/4A inhibitors other than telaprevir, simeprevir, boceprevir)-efficacy not demonstrated
Side effects
For elbasvir with grazoprevir Common or very common Alopecia; anxiety; appetite decreased; arthralgia; asthenia; constipation; depression; diarrhoea; dizziness; dry mouth; gastrointestinal discomfort; headache; insomnia; irritability; myalgia; nausea; pruritus; vomiting Frequency not known Anaemia; hepatitis B reactivation; transient ischaemic attack
Pregnancy
For elbasvir with grazoprevir Manufacturer advises use only if potential benefit outweighs risk.
Breast feeding
For elbasvir with grazoprevir Manufacturer advises avoid-present in milk in animal studies.
Hepatic impairment
For elbasvir with grazoprevir Manufacturer advises avoid in moderate to severe impairment.
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Elbasvir with grazoprevir in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

